A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).
Thomas Powles
Consultant or Advisory Role - Genentech
Stephane Oudard
Consultant or Advisory Role - Roche
Bernard J. Escudier
No relevant relationships to disclose
Janet Elizabeth Brown
No relevant relationships to disclose
Robert E. Hawkins
No relevant relationships to disclose
Daniel E. Castellano
No relevant relationships to disclose
Alain Ravaud
No relevant relationships to disclose
Michael D. Staehler
Consultant or Advisory Role - Genentech
Brian I. Rini
No relevant relationships to disclose
Wei Lin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Bridget O'Keeffe
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Michelle Byrtek
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Mark Lackner
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Jill M Spoerke
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Joseph A. Ware
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Rui Zhu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Robert J. Motzer
Consultant or Advisory Role - Genentech